S'abonner

In vitro antifungal and antibiofilm activities of novel sulfonyl hydrazone derivatives against Candida spp. - 17/03/23

Doi : 10.1016/j.mycmed.2022.101327 
Merve Aydin a, , Ali Ozturk b, Tugce Duran c, Ummuhan Ozdemir Ozmen d, Esra Sumlu e, Esra Bilen Ayan d, Emine Nedime Korucu f
a Department of Medical Microbiology, Faculty of Medicine, KTO Karatay University, Konya, Turkey 
b Department of Medical Microbiology, Faculty of Medicine, Niğde Ömer Halisdemir University, Niğde, Turkey 
c Department of Medical Genetics, Faculty of Medicine, KTO Karatay University, Konya, Turkey 
d Department of Chemistry, Faculty of Science, Gazi University, Ankara, Turkey 
e Department of Medical Pharmacology, Faculty of Medicine, KTO Karatay University, Konya, Turkey 
f Department of Molecular Biology and Genetics, Faculty of Science, Necmettin Erbakan University, Konya, Turkey 

Corresponding author.

Abstract

Background

The aim of this study was to investigate the antifungal and antibiofilm activity of the new sulfonyl hydrazones compound derived from sulphonamides.

Methods

In this study, new sulfonyl hydrazone series were synthesized via a green chemistry method. The structures of the synthesized compounds were characterized by elemental analyses and spectroscopic methods. The antifungal activities of the Anaf compounds against Candida strains under planktonic conditions were tested. The biofilm-forming ability of Candida strains was determined and the inhibitory effects of Anaf compounds on Candida biofilms compared with fluconazole were measured by MTT assay. Expression analysis of biofilm-related genes was investigated with qRT-PCR. The statistical analysis was performed using a one-way ANOVA test.

Candida

strains was determined and the inhibitory effects of Anaf compounds on Candida biofilms compared with fluconazole were measured by MTT assay. Expression analysis of biofilm-related genes was investigated with qRT-PCR. The statistical analysis was performed using a one-way ANOVA test.

Results

A total of 16 (45.7%) out of 35 Candida isolates were determined as strong biofilm producers in this study. C. albicans was the most biofilm producer, followed by C. krusei and C. lusitaniae. The Anaf compounds had a broad spectrum of activity with MIC values ranging from 4 μg/ml to 64 μg/ml. Our data indicated that the Anaf compound had a significant effect on inhibiting biofilm formation in both fluconazole-susceptible and -resistant strains. The expression levels of hypha-specific genes als3, hwp1, ece1 and sap5 were downregulated by Anaf compounds.

Conclusions

Our study revealed that the Anaf compounds had antifungal activity and inhibited fungal biofilms, which may be related to the suppression of C. albicans adherence and hyphal formation. These results suggest that Anaf compounds may have therapeutic potential for the treatment and prevention of biofilm-associated Candida infections.

Le texte complet de cet article est disponible en PDF.

abstract




Image, graphical abstract

Le texte complet de cet article est disponible en PDF.

Keywords : Biofilm, Candida, Antifungal, Antibiofilm, New sulfonyl hydrazone, Biofilm-related genes


Plan


© 2022  SFMM. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 33 - N° 1

Article 101327- mars 2023 Retour au numéro
Article précédent Article précédent
  • Frequencies of pathogenic CFTR variants in Greek cystic fibrosis patients with allergic bronchopulmonary aspergillosis and Aspergillus fumigatus chronic colonization: A retrospective cohort study
  • Maria Noni, Anna Katelari, Myrto Poulou, Diomidis Ioannidis, Efthymia-Maria Kapasouri, Maria Tzetis, Stavros-Eleftherios Doudounakis, Christina Kanaka-Gantenbein, Vana Spoulou
| Article suivant Article suivant
  • Simulated vaginal fluid: Candida resistant strains’ biofilm characterization and vapor phase of essential oil effect
  • Liliana Fernandes, Raquel Costa, Mariana Henriques, Maria Elisa Rodrigues

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.